Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report

The patient received afatinib for recurrent lung cancer (a) with a partial response (b). The patient had progressed disease (c) and rebiopsy of lung tumor showed positiveEGFR exon 20 p.T790M mutation. He had a partial response to osimertinib treatment (d) AbstractTyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) are the standard treatment for lung cancer patients with activatingEGFR mutation. The traditional direct polymerase chain reaction (PCR) has lower sensitivity in the detection ofEGFR mutations in patient tissue samples. Whilst PCR amplification kits increase the sensitivity in detecting some types ofEGFR mutations, not many types of rare mutations are found. Here, we report a patient who had lung adenocarcinoma harboringEGFR T751_I759delinsS mutation and had good response to afatinib initially and osimertinib after developing resistance to afatinib. This rareEGFR mutation was not detected by Scorpion and ARMS method but was found using the next-generation sequencing method. There are less prospective trials in the treatment of lung adenocarcinoma with very rareEGFR mutations. Our case report could therefore provide clinical experience to the clinicians in the management of their patients.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research